ITEM SPECIFICS
-
Brand
Unbranded
-
origin
Republic of Korea
-
Size(Capacity)
1box 48tests
PRODUCT DESCRIPTION
EuDx™-MDR TB Detection Kit
Description
EuDx™-MDR TB Detection Kit (Multidrug-resistant TB, MDR TB)
diagnosis reagent swiftly analyzes the presence or absence
of mutations of rpoB, katG, inhA genes, which are the causation
genes of drug-resistance, in the genes IS6110, rpoB, RIF,
and INH through PCR. EuDx™-MDR TB Detection Kit (Multidrug-resistant TB, MDR TB)
is an In Vitro Diagnostic medical device aimed to aid in the diagnosis of TB pathogen infections and the determination of the drug-resistance of such TB pathogens
in suspected patients.
EuDx™-MDR TB Detection Kit (Multidrug-resistant TB, MDR TB)
diagnosis reagent swiftly analyzes the presence or absence
of mutations of rpoB, katG, inhA genes, which are the causation
genes of drug-resistance, in the genes IS6110, rpoB, RIF,
and INH through PCR. EuDx™-MDR TB Detection Kit (Multidrug-resistant TB, MDR TB)
is an In Vitro Diagnostic medical device aimed to aid in the diagnosis of TB pathogen infections and the determination of the drug-resistance of such TB pathogens
in suspected patients.
Features
1) High Responsiveness and Specificity
- MTB and MDR TB → TB (IS6110) + 6 types of mutations
- Simultaneous gene testing (Multiplex PCR)
- Fusion of various PCR technology (Real-time PCR + MGB TaqMan Probe Assay)
2) Minimizes pollution and Provides credible data
- 3 step PCR One tube test (prevents cross-pollution)
- provides credible results through Internal control (IC)
3) Increased patient satisfaction through swift diagnosis (85 minutes required)
- reduction of inspection time through simultaneous detection of TB and multidrug-resistant bacteria and increased possibility of early diagnosis and treatment
Currently, products sold for the diagnosis of drug-resistant TB can be summarized into three types. The product developed by LG Life Sciences and Hain Lifescience in Germany, currently holding the largest domestic market share, first extracts the DNA from the sample and amplifies the mutations of rpoB, katG, inhA genes, which are the causation genes of drug-resistance in the pathogens, through PCR. The resulting product then goes through hybridization with a membrane combined with a probe in order to check for mutations, but this process has a disadvantage - diagnosis takes 3-4 hours to complete. The second utilizes melting analysis and PCR developed by Seegene, and this analysis takes around 3 hours, but its share in the domestic market is negligible. Lastly, there is the Xpert RIF product developed by Cepheid, and this is the most popular product internationally. This product prioritizes analyzing small numbers of samples instead of large amounts, and it has a disadvantage in that it only checks for resistance towards Rifampicin in addition to being expensive. The product developed at Eudipia has a short diagnosis time of 90 minutes and it tests for both Rifampicin and Isoniazid simultaneously. No other comparable product has been manufactured thus far.
- MTB and MDR TB → TB (IS6110) + 6 types of mutations
- Simultaneous gene testing (Multiplex PCR)
- Fusion of various PCR technology (Real-time PCR + MGB TaqMan Probe Assay)
2) Minimizes pollution and Provides credible data
- 3 step PCR One tube test (prevents cross-pollution)
- provides credible results through Internal control (IC)
3) Increased patient satisfaction through swift diagnosis (85 minutes required)
- reduction of inspection time through simultaneous detection of TB and multidrug-resistant bacteria and increased possibility of early diagnosis and treatment
Currently, products sold for the diagnosis of drug-resistant TB can be summarized into three types. The product developed by LG Life Sciences and Hain Lifescience in Germany, currently holding the largest domestic market share, first extracts the DNA from the sample and amplifies the mutations of rpoB, katG, inhA genes, which are the causation genes of drug-resistance in the pathogens, through PCR. The resulting product then goes through hybridization with a membrane combined with a probe in order to check for mutations, but this process has a disadvantage - diagnosis takes 3-4 hours to complete. The second utilizes melting analysis and PCR developed by Seegene, and this analysis takes around 3 hours, but its share in the domestic market is negligible. Lastly, there is the Xpert RIF product developed by Cepheid, and this is the most popular product internationally. This product prioritizes analyzing small numbers of samples instead of large amounts, and it has a disadvantage in that it only checks for resistance towards Rifampicin in addition to being expensive. The product developed at Eudipia has a short diagnosis time of 90 minutes and it tests for both Rifampicin and Isoniazid simultaneously. No other comparable product has been manufactured thus far.
Specification
Product Composition
- 2X qPCR Premix
- 4X Reaction Mixture
(Primer/Probe +
Internal Control)
- Positive Control DNA
- Nuclease Free Water
- 2X qPCR Premix
- 4X Reaction Mixture
(Primer/Probe +
Internal Control)
- Positive Control DNA
- Nuclease Free Water
Others
Product Specification
-1box 48tests
-1box 48tests
PAYMENTS DETAILS
This supplier supports payments for offline orders
- Telegraphic Transfer : T/T
- Letter of Credit : L/C(sight)
- Name : In Soo Kim
SHIPPING
Shipping from :
Republic of Korea
- 194-41 Osongsaengmyeong 1-ro Osong-eup Heungdeok-gu, Cheongju-si, Chungcheongbuk-do Korea (28160)
EuDiPia Co. Ltd.
The person in charge
In Soo KimAddress
194-41 Osongsaengmyeong 1-ro Osong-eup Heungdeok-gu, Cheongju-si, Chungcheongbuk-do Korea (28160)
Introduction
Eudipia Co., Ltd. is a professional diagnostics company mainly providing molecular diagnosis services. We started with the diagnosis of tuberculosis and we plan to expand our diagnostic products to various fields.
Eudipia Co., Ltd. was established with the goal of becoming the absolute best
in the world in the diagnosis of tuberculosis.
Since then we plan to expand our diagnostics to the fields of respiratory diseases
and early cancer diagnosis.
We named our company Eudipia in the hope to create an utopia through diagnosis.
Furthermore, Swift and precise Fully Automated POCT system development for improved
user convenience is currently in development, and diagnostics for respiratory viruses,
MDR TB, venereal diseases, dengue, malaria, etc. are set to be released in 2017.
Next, Eupidia Co., Ltd. plans to branch out into the world by establishing contracts with dealers and distributors through discovery of transaction lines country by country.
-
- Business Type :
- Manufacturer
-
- Main Product :
- EuDx™-MTB Detection Kit, MTB One-tube Nested Multiplex real-time PCR
-
- Established :
- 2012-09-01
-
- Total Annual Revenue :
- 6 million to 10 billion (KRW)
-
- Total Employees :
- 11~50 people
Please suggest a variety of your ideas such as design, impact, enhancements, etc
Captcha Required
Please enter the text on the left image to prevent automatic input.
0 / 4000
질문이 없습니다.
CUSTOMER REVIEWS (0)
TRADE EXPERIENCE
-
- Total revenue
- 6 million to 10 billion (KRW)
-
- Total export revenue (previous year in USD)
- 10
-
- Number of foreign trade employees
- 11~50 people
COMPARISON TO SIMILAR ITEMS more
- No Items
- supplier level
-
GOLD
- EuDiPia Co. Ltd. Seller's Store
- Seller's Store url
- Response Level
★ ★ ★ ★ ★
- Supplier Level
★ ★ ★ ★ ★
- Transaction Level
★ ★ ★ ★ ★
SUPPLIER BEST
![EuDx™-ufPCR System[ultra fast system]](/image/goodsImage.do?goods_no=GS2017110617520&image_se_code=MAIN_THUMB174)
